Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
- PMID:26971233
- DOI: 10.1016/j.euroneuro.2016.02.013
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
Abstract
Escitalopram is the most selective of the serotonin reuptake inhibitor (SSRI) antidepressants. We conducted a meta-analysis of placebo-controlled studies where escitalopram was used to treat patients with social anxiety disorder (SAD). Data from all randomised, double-blind placebo-controlled studies in SAD with escitalopram from both specialist settings and general practice were used. Patients met the DSM-IV criteria for SAD, were ≥18 years old, and had a Liebowitz Social Anxiety Scale (LSAS) ≥60. The primary outcome measure was the estimated treatment difference in LSAS total score at Week 12. Secondary outcome measures included the estimated treatment difference in the Clinical Global Impression-Severity (CGI-S) score at Week 12. A total of 1598 patients from 3 randomised controlled trials were included in the analyses. Escitalopram (n=1061) was superior to placebo (n=537), with an estimated treatment difference on the LSAS of -9.2 points (95%CI: [-14.4; -4.0], p<0.01) (escitalopram 5mg/day), -4.6 points (95%CI: [-8.1; -1.0], p<0.01) (escitalopram 10mg/day), -10.1 points (95%CI: [-13.7; -6.5], p<0.01) (escitalopram 20mg/day) and -7.3 points (95%CI: [-12.3; -2.2], p<0.01) (escitalopram 10-20mg/day). For the CGI-S, the corresponding values were -0.55 points (95%CI: [-0.79; -0.31], p<0.01) (escitalopram 5mg/day), -0.26 points (95%CI: [-0.42; -0.10], p<0.01) (escitalopram 10mg/day), -0.48 points (95%CI: [-0.64; -0.31], p<0.01) (escitalopram 20mg/day) and -0.29 points (95%CI: [-0.51; -0.07], p<0.05) (escitalopram 10-20mg/day). The withdrawal rate due to adverse events was 7.2% for escitalopram, compared with 4.3% for placebo (p<0.05). In this meta-analysis, all doses of escitalopram showed significant superiority in efficacy versus placebo in the treatment of patients with SAD.
Keywords: Efficacy; Escitalopram; LSAS; Meta-analysis; Placebo; Social anxiety disorder.
Crown Copyright © 2016. Published by Elsevier B.V. All rights reserved.
Similar articles
- A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan.Asakura S, Hayano T, Hagino A, Koyama T.Asakura S, et al.Curr Med Res Opin. 2016;32(4):749-57. doi: 10.1185/03007995.2016.1146663. Epub 2016 Feb 5.Curr Med Res Opin. 2016.PMID:26808688Clinical Trial.
- Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.Kennedy SH, Andersen HF, Lam RW.Kennedy SH, et al.J Psychiatry Neurosci. 2006 Mar;31(2):122-31.J Psychiatry Neurosci. 2006.PMID:16575428Free PMC article.
- [Efficacy and tolerability of escitalopram in anxiety disorders: a review].Pelissolo A.Pelissolo A.Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15.Encephale. 2008.PMID:18922243Review.French.
- Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study.Lader M, Stender K, Bürger V, Nil R.Lader M, et al.Depress Anxiety. 2004;19(4):241-8. doi: 10.1002/da.20014.Depress Anxiety. 2004.PMID:15274173Clinical Trial.
- Escitalopram : a review of its use in the management of major depressive and anxiety disorders.Waugh J, Goa KL.Waugh J, et al.CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004.CNS Drugs. 2003.PMID:12665392Review.
Cited by
- Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial.Mahajan SS, Tandon VR, Arora M, Mahajan A, Kotwal S.Mahajan SS, et al.J Midlife Health. 2019 Jul-Sep;10(3):141-146. doi: 10.4103/jmh.JMH_139_18.J Midlife Health. 2019.PMID:31579188Free PMC article.
- Descended Social Anxiety Disorder and Craving in Women Heroin Dependence Through Exercise Alerts Plasma Oxytocin Levels.Wang JS, Liu JL, Zhang J, Tan J, Huang T, Lu CX, Peng XY, Guo Y, Zheng L.Wang JS, et al.Front Psychiatry. 2021 Nov 26;12:624993. doi: 10.3389/fpsyt.2021.624993. eCollection 2021.Front Psychiatry. 2021.PMID:34899404Free PMC article.
- Modulation of functional networks related to the serotonin neurotransmitter system by citalopram: Evidence from a multimodal neuroimaging study.Boucherie DE, Reneman L, Booij J, Martins D, Dipasquale O, Schrantee A.Boucherie DE, et al.J Psychopharmacol. 2023 Dec;37(12):1209-1217. doi: 10.1177/02698811231211154. Epub 2023 Nov 10.J Psychopharmacol. 2023.PMID:37947344Free PMC article.Clinical Trial.
- Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S.Möller HJ, et al.Eur Arch Psychiatry Clin Neurosci. 2019 Mar;269(2):183-193. doi: 10.1007/s00406-017-0852-4. Epub 2017 Nov 17.Eur Arch Psychiatry Clin Neurosci. 2019.PMID:29150713Free PMC article.
- Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial.Faria V, Gingnell M, Hoppe JM, Hjorth O, Alaie I, Frick A, Hultberg S, Wahlstedt K, Engman J, Månsson KNT, Carlbring P, Andersson G, Reis M, Larsson EM, Fredrikson M, Furmark T.Faria V, et al.EBioMedicine. 2017 Oct;24:179-188. doi: 10.1016/j.ebiom.2017.09.031. Epub 2017 Sep 27.EBioMedicine. 2017.PMID:29033138Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous